ACTalks Blogs

 View Only

Free Educational Webinar: Safety Assessment of Metabolites in Drug Development: Current Perspective

By Elisa Turner posted 01-22-2020 02:40 PM

  

Having trouble viewing this message? A version is available online.
Please forward this announcement to others who you feel may be interested.

You are Invited to Participate in a Free Educational Webinar

Safety Assessment of Metabolites in Drug Development: Current Perspective

Wednesday, February 12, 2020 at 11:00 AM EST

Hosted by American College of Toxicology
With support from Society of Toxicologic Pathology
and Safety Pharmacology Society

 

Speaker:

Galvis_Carol_web.jpg

Carol M. Galvis, PhD

Lead Pharmacologist 
US Food and Drug Administration

 

This webinar will provide an overview of safety assessment of metabolites in drug development. The speaker will discuss relevant guidance documents and will describe important considerations for the safety assessment of drug metabolites, including type of studies required and timing of submission to regulatory agencies. This topic has evolved over the last few years and the speaker will incorporate FDA recent case studies that will provide participants insight into the regulatory decision-making process regarding this topic. Examples will include unique human metabolites, disproportionate human metabolites, metabolites that are acyl glucuronides, and examples of safety assessment of drug metabolites for severe, debilitating, and life-threatening (SDLT) conditions.

Webinar Registration

There is no fee but advance registration is required.

Please forward this invitation to others you feel might be interested in this webinar. If you missed an ACT Signature Webinar visit the archives.

 

11190 Sunrise Valley Drive, Suite 300, Reston, VA 20191
Tel: 703.547.0875    Fax: 703.438.3113    Email: acthq@actox.org    Website: www.actox.org   Twitter: @ACToxicology

You may view the ACT Privacy Policy, provide consent to ACT to email you communications or unsubscribe to stop receiving further ACT communication.
Privacy Policy   |   Provide Consent   |   Unsubscribe

 

0 comments
0 views